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A major challenge in cystic fibrosis (CF) research is applying mutation-specific therapy to indi-
vidual patients with diverse and rare CF transmembrane conductance regulator (CFTR) geno-
types. Read-through agents are currently the most promising approach for Class I mutations
that introduce premature termination codons (PTCs) into CFTR mRNA. However, variations in
degradation of PTC containing transcripts by nonsense mediated decay (NMD)might lower read-
through efficacy. Allele specific quantitative real time (qRT)-PCR was used to measure variations
in CFTRmRNA abundance for several PTCmutations in respiratory cells and intestinal organoids.
The majority of PTC mutations were associated with reduced levels of relative mRNA transcript
abundance (∼33% and 26% of total CFTR mRNA in respiratory cells and intestinal organoids,
respectively, compared to>50% for non-PTC causing mutations). These levels were generally not
affected by PTC mutation type or position, but there could be twofold variations between indi-
viduals bearing the same genotype. Most PTC mutations in CFTR are subject to similar levels of
NMD,which reduce but do not abolish PTCbearingmRNAs.Measurement of individual NMD lev-
els in intestinal organoids and HNE cells might, therefore, be useful in predicting efficacy of PTC
read-through in the context of personalized CFTRmodulator therapy.
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1 INTRODUCTION
Amajor challenge in current cystic fibrosis (CF) research is developing
CF transmembrane conductance regulator (CFTR) mutation class-
specific therapies (Veit et al., 2016). Currently, six classes of mutations
that may be susceptible to CFTR drug-based rescue are recognized
plus a seventh class for which CFTR pharmacological rescue is unlikely
(De Boeck & Amaral, 2016). A significant proportion of the ∼2000
potentially disease causing CFTR variants identified to date are Class
I mutations, i.e., those introducing an in-frame premature termination
codon (PTC) into theCFTRmessengerRNA (CFTR1mutationdatabase:
www.genet.sickkids.on.ca). However, besides these in-frame nonsense
mutations (8% of the total in CF) PTCs can also be introduced by
frameshift or splicing mutations (Oren, Pranke, Kerem, & Sermet-
Gaudelus, 2017; Sanz et al., 2010), representing approximately 2%
and 12% of CFTR mutations, respectively. Translation of an mRNA
transcript bearing a PTC will produce a truncated and most likely non-
functional protein, but this is largely avoided by an mRNA surveillance
mechanism termed nonsense mediated decay (NMD, Frischmeyer &
Dietz, 1999). NMD is an important posttranscriptional quality control
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mechanism that reduces the abundance of PTC-transcripts (Maquat,
1995), thereby avoiding synthesis of potentially toxic truncated pro-
teins and associated cellular stress in the form of the unfolded protein
response (UPF; Walter & Ron, 2011). The absence of functional CFTR
protein resulting from PTCs translates into severe CF phenotypes that
are usually associated with these mutations (Keeling, Wang, Conard,
& Bedwell, 2012) comparable to those of the most common CFTR
mutation, F508del (c.1521_1523delCTT; Shoshani et al., 1992).
One potential treatment for PTC mutations is the use of read-
through agents such as aminoglycoside antibiotics like gentamycin or
tobramycin (Hermann, 2007), which can promote insertion of near-
cognate amino acids in place of the PTC (Sermet-Gaudelus & Namy,
2016), thereby allowing translation of a full-length and potentially
functional protein. However, the reduced abundance of PTC-bearing
mRNAs by NMD might reduce the effectiveness of PTC read-through
therapies by removing their substrate (Linde, Boelz, Nissim-Rafinia,
et al., 2007). Indeed, variations in NMD efficiency have been reported
among different cell types and genes (Linde, Boelz, Neu-Yilik, Kulozik,
& Kerem, 2007b). The effect of NMD might also vary according to
the position and/or sequence context of a specific mutation: for exam-
ple, PTCs located less than 50–55 nt upstream of the last exon–exon
junction, or in close proximity to the normal initiation or termination
codons may fail to trigger NMD (Inácio et al., 2004; Nagy & Maquat,
1998).
In this study, we determined the extent to which a variety of CFTR
PTC-causing mutations affect mRNA abundance via NMD in an allele
specific manner in native human nasal epithelial (HNE) cells, so as
to unravel whether mRNA levels vary according to mutation type,
position or even among different individuals with the same muta-
tion. We also assessed the suitability of intestinal organoids as mod-
els for assessing this phenomenon, by comparison with respiratory
cells/tissues. Our data provide a basis for the development of read-
through therapies targeting Class I mutations in CFTR.
2 MATERIALS AND METHODS
2.1 Nomenclature
In the present work, the legacy mutation names are given (CFTR1:
www.genet.sickkids.on.ca) followed upon first use by the HGVS
cDNA name in brackets, based on the CFTR reference sequence
NM_000492.3. In tables, both legacy names and HGVS variant
nomenclature are given for clarity.
2.2 Participants and nasal respiratory epithelial
cell collection
The studywas conducted at the Faculty of Sciences of theUniversity of
Lisboa with samples collected at the Adult and Pediatric CF Clinics of
the Hospital de Santa Maria in Lisboa, and was approved by the Santa
Maria Hospital Ethical Review Board. Informed consent for both nasal
brushing and rectal biopsy was obtained from each participant, or
parent/tutor where the participant was a minor. To be eligible for the
study, individuals with CF with PTC causing mutations in CFTR were
selected, either homozygous or in heterozygosity with F508del or
other mutations (PTC/PTC, PTC/F508del, or PTC/other, respectively).
Samples from individuals with other genotypes (with non PTC muta-
tions: F508del/other, F508del/F508del, WT/WT, or other/other) were
also analyzed, as control samples. HNE cell samples were also sent to
Lisboa from two other participating centres (Pediatric Pulmonology
& CF Unit, Hospital Universitari, Vall d'Hebron, Barcelona, Spain;
Human Genetics Department, Faculty of Medical Sciences, University
of Campinas, Brazil) as Trizol lysates (Thermofisher Scientific) on
dry ice, having been collected and processed in the same way, i.e.,
by bilateral brushing (Paro Isola Long 3 mm, Paro, Esro AG, Switzer-
land) of the nasal mucosa, as previously described (Beck et al., 1999;
Harris et al., 2004). In some cases, an aliquot was set aside for con-
ditional reprogramming culture (CRC-HNE), and the remainder was
lysed in Trizol reagent for extraction of total RNA.
2.3 Conditionally reprogrammed cell culture of HNE
Conditional reprogrammed cell (CRC) culture of HNEs was performed
as previously reported (Reynolds et al., 2016). Briefly, following brush-
ing the nasal cell samples were washed three times in growth medium
and pelleted by gentle centrifugation before addition to a feeder layer
of irradiated NIH-3T3 fibroblast cells (ATCC Catalog #CRL-1658) that
had been grown to near confluence and irradiated by exposure to a
Cobalt 60 gamma ray source (1.60 kGy/h) with a total dose of 31 Gy
(3100 rads). The co-culture was maintained in F12 medium containing
10uM Y-27632 Rho Kinase inhibitor. After 1 week of culturing, small
islands of epithelial cells appeared among the feeder layer cells. When
these epithelial cell islands had grown to cover 90% of the culture dish
surface area, differential trypsinization was performed for isolation
of the CRC-HNEs. Air-liquid interface (ALI) cultures were then estab-
lished on 0.4 𝜇M Costar Transwell permeable support filters (Corn-
ing) pre-coated with human placental type IV collagen. The cells were
seeded at a density of 3×105 cells/cm2 and cultured in F12 medium
withoutRhoKinase inhibitor or feeder layer. After 5–7days,when cells
had reached confluence on filters, the medium was removed from the
apical surface, and the cellswere thengrownat theALI for21daysuntil
polarized. They were then lysed with Trizol and RNA was extracted as
described below.
2.4 Intestinal organoid cultures
Crypt isolation and human organoid culturing were carried out as
described previously (Dekkers et al., 2013; Sato & Clevers, 2013;
Sato et al., 2009; Sato et al., 2011). Briefly, three to four superficial
rectal mucosa specimens (3-4 mm in diameter) were recovered with
colon forceps and immediately placed into culture medium. Then, the
biopsies were washed with PBS and treated with 10 mM EDTA for
90–120min at 4ºC.Cryptswere isolatedby centrifugation and isolated
crypts cultured in 50%Matrigel R© (growth factor free, phenol-free, BD
biosciences). Isolated crypts were seeded (∼10–30 crypts in 3×10 𝜇L
Matrigel R© droplets per well) in prewarmed 24-well plates. The
Matrigel R© was polymerized for 10–15 min at 37ºC and surrounded
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by complete culture medium consisting of: advanced DMEM/F12 sup-
plementedwith penicillin/streptomycin, 10mMHEPES, Glutamax, N2,
B27 (all purchased from Invitrogen), 1𝜇M N-acetylcysteine (Sigma),
and growth factors: 50 ng/mL mEGF, 50% Wnt-3a-conditioning
medium (WCM) and 10% Noggin-conditioned medium, 20% Rspo1-
conditioned medium (RCM), 10 𝜇M nicotinamide (Sigma), 500 nm
A83-01 (Tocris), and 10𝜇M SB 202190 (Sigma). Antibiotics were
added to growthmedium (Primocin 1:500, Invivogen; Vancomycin and
Gentamycin, Sigma) during the first weeks. The medium was changed
every alternate day and organoids were passaged after 7–9 days of
culturing. Each organoid RNA sample was extracted from three wells.
2.5 Real time PCR
To determine relative quantitative abundance of CFTR transcripts
in an allele specific manner, we used the ΔΔCT qRT-PCR method to
compare expression of the F508del allele with the other allele by
using primer pairs that reliably distinguish between the 3 bp missing
(c.1521_1523delCTT) on the F508del allele, as previously described
(Awatade et al., 2015). Briefly, RNA was extracted (Trizol method—
Invitrogen—or Macherey Nagel Nucleospin columns), quantified by
Nanodrop spectrophotometry and digested with DNase I. Approxi-
mately 1 𝜇g of total RNA was subjected to reverse transcription (RT)
with random primers to produce cDNA (NZYTech, Lisboa, Portugal).
cDNA was diluted to give a final reaction mixture concentration
between 0.5 and 1.5 ng/𝜇L. Non-F508del and F508del transcripts
were then amplified in separate reactions by qRT-PCR in triplicate
using the SsoFast EvaGreen system (Bio-Rad,Hercules, CA),with allele
specific primers (see Supporting Information Table S1). Melt curves
were checked to confirm amplification of single products, and negative
controls were confirmed to be free of nonspecific amplification at 40
cycles. Products were quantified using the ΔΔCT method, normalized
using as a reference gene either CAP-1 (adenylate cyclase associated
protein 1) or ACTB (𝛽 actin), and fold change (FC) between F508del
and non-F508del products was calculated using the formula FC =
2(–ΔΔCT). Abundance of CFTR transcripts derived from each allele
was then expressed as a percentage of total CFTR. For calculation
of “percent transcript degradation” of PTC transcripts, we used the
formula: % degradation = ((Y–X)/Y) × 100, where X and Y are percent
CFTR transcript derived from PTC and non-PTC alleles, respectively,
assuming 50% transcript from each allele in the absence of PTC
related NMD.
For relative quantification of whole CFTR mRNA, a different
forward primer, avoiding the F508del mutation, was used (5′-
ACTGGAGCAGGCAAGACTTC-3′).
2.6 PTCmutation specific primers
As many of the PTC samples obtained were not from individuals
heterozygous for the F508del mutation, we designed primer sets
to distinguish between alleles based on some of the more common
PTC mutations encountered, namely E60X (c.178G>T), G542X
(c.1624G>T), R553X (c.1657C>T), Y1092X (c.3276C>A), R1162X
(c.3484C>T), and W1282X (c.3846G>A). These primer sets were
constrained by the position of the nucleotide substitution, and in
most cases the single 3′ terminal mismatch was not enough to reliably
distinguish between alleles. In order to increase specificity of the
PTC primers, a strong mismatch between primer and target sequence
(G:A or A:G for all primer sets with the exception of the Y1092X
primers, which used a C:Cmismatch) was introduced at the -2, -3, or -4
position (with respect to the 3′ terminus) of each primer. The aim was
to reduce the overall binding affinity of the 3’ region of the primers,
while increasing the influence of the final base on target sequence
specificity (Kwok et al., 1990). This mismatch amplification mutation
assay (“MAMA”) has previously been shown to be capable of detecting
30 copies of a mutant allele among 3 × 106 copies of a wt allele (Cha,
Zarbl, Keohavong, & Thilly, 1992). The primer sets for PTC mutation
discrimination were designed using Primer3 software (Untergasser
et al., 2012) with mismatch bases incorporated, are shown in Support-
ing Information Table S1. Primer specificity was confirmed by control
amplification of plasmid CFTRDNA.
3 RESULTS
3.1 Samples and genotypes
The samples used for this study and their respective genotypes
are shown in Supporting Information Table S2. In summary, we
used samples from a total of 86 individuals, of which 53 were res-
piratory cells (mainly freshly collected native HNE cells), and the
remainder were intestinal organoid samples derived from 33 individ-
uals. CRC-HNE, organoid, rectal biopsy, and bronchial cell samples
were also utilized, derived in a few cases from patients who also
provided nasal cell samples. Among the 45 CFTR genotypes repre-
sented (Supporting Information Table S2), the greatest number were
F508del/PTC heterozygous combinations, of which there were 18,
the most abundant being G542X/F508del and R1162X/F508del. PTC
mutations were also represented in 7 PTC/PTC (e.g., G542X/G542X,
W1282X/W1282X, and G542X/R553X) and 11 PTC/other com-
binations (e.g., p.G542X/R334W [c.1000C>T]). We included some
non-PTCCFTR genotypes as non-NMDcausing controls, and used both
WT/WT and F508del/F508del homozygotes as primer controls. We
also included a number of CRC-HNE samples, primary HBE cells, and
rectal biopsies (i.e., non-cultured) when available.
3.2 RelativemRNA abundance for PTCmutations
in trans with F508del
Data on relative abundance of CFTR mRNA as measured by allele
specific qRT-PCR using primers discriminating between presence or
absence of the F508del mutation in heterozygous samples, are com-
piled in Table 1 (for respiratory cells, principally native HNEs, but
also primary HBE cells and CRC-HNEs) and Table 2 (for intestinal
organoids). All these data are also summarized in Figure 1.
As expected, most PTC causing CFTR mutations were associated
with reduced mRNA abundance, as measured by allele specific qRT-
PCR. For example, in HNE samples from 10 CF patients with the
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native HNE) N (patients)
Percentage of total CFTR
mRNA represented by PTC







S4X c.11C>A 1 47.8% 8.4%
G542X c.1624G>T 10 28.7% (±2.6) 59.8%
G542X c.1624G>T Primary HBE 1 21% 73.4%
1811+1.6kbA>G c.1679+1634A>G 1 37.6% 39.7%
2183AA>G c.2051_2052delAAinsG 3 37.4% (±7.4) 40.3%
Q890X c.2668C>T 2 38% 38.7%
3272-26A>G c.3140-26A>G 1 34.9% 46.4%
Y1092X c.3276C>A Primary HBE 1 26% 64.9%
3886insA c.3754_3755insA 1 33% 50.7%
3886insA c.3754_3755insA CRC-HNE 1 27% 63%
Other (non PTC)
P205S c.613C>T 1 61% N/A
R334W c.1000C>T 2 53% N/A
R334W c.1000C>T CRC-HNE 3 50% (±1.2) N/A
R347P c.1040G>C Primary HBE 1 52% N/A
A561E c.1682C>A 1 57% N/A
1812-1G>A c.1680-1G>A 1 63.7% N/A
aBased onNCBI Reference Sequence for CFTR: NM_000492.3.
Abbreviations: HNE, human nasal epithelial cells; CRC, conditionally reprogrammedHNE cells; HBE, human bronchial epithelial cells.
F508del/G542X genotype, a mean 28.7 ± 2.6% (SEM) of total CFTR
mRNAwas found tobederived fromtheG542Xallele,with the remain-
der corresponding to F508del-CFTRmRNA. Assuming that 50%mRNA
is initially transcribed from each allele, it was calculated that on aver-
age 59.8% of the transcribedG542X-CFTRmRNAwas degraded, most
likely by NMD. Among these 10 G542X/F508del samples, abundance
of PTC-bearing mRNA varied between 13.5% and 38.2%, supporting
previous finding that there are inter-individual differences in NMD,
which in turn might influence the effectiveness of PTC read-through
agents (Linde, Boelz, Nissim-Rafinia, et al., 2007a).
Similar data were obtained in respiratory tissues for other PTC
mutations, including other Class I PTC mutants Q890X (c.2668C>T)
and Y1092X, frameshift and splicing mutants 1811+1.6kbA>G
(c.1679+1634A>G), 2183AA>G (c.2051_2052delAAinsG), 3272-
26A>G (c.3140-26A>G), and 3886insA (c.3754_3755insA), which
suffered between 39% and 63% transcript degradation. As expected,
non-PTC mutants (P205S [c.613C>T], R334W, A561E [c.1682C>A])
were present at approximately 55% of mRNA abundance with little
variation. Interestingly, the S4X (c.11C>A) and 1812-1G>A (c.1680-
1G>A)mutants did not show evidence for NMD. Data generated using
primary HBE cells and CRC-HNEs showed no significant differences
from those in native HNEs, and can be considered equivalent.
Table 2 presents the combined results from intestinal organoid
samples, which had F508del on the second allele. As seen in res-
piratory tissues, PTC causing CFTR mutations were also associated
with reduced mRNA abundance in organoids (from 17.4% for Y1092X
to 39% for E60X, with 79% and 36% of PTC-bearing transcripts
degraded, respectively). Once again, the splicingmutants 2789+5G>A
(c.2657+5G>A), 3849+10kbC>T (c.3717+12191C>T), and 3500–
2A>G (c.3368-2A>G) were associated with a similar level of tran-
script degradation (around 70% in each case), which is to be expected,
as these splicing defects introduce PTCs following a shift in reading
frame in the aberrantly spliced mRNA. This was, however, not the case
for the 711+1G>T (c.579+1G>T) mutation, which does not cause a
frameshift. The dele2,3_21 kb (c.54-5940_273+10250del21kb) muta-
tion, which was predicted to cause a reading frame shift with the
consequent introduction of a PTC, was not, however, associated with
reduced mRNA abundance. As expected, non-PTC mutants (R334W,
A455E [c.1364C>A]) were present at around 50% of mRNA abun-
dance, as in respiratory cells. The data presented here confirm that,
in general, intestinal organoids appear to be a valid surrogate for the
study of allele specific CFTR mRNA abundance in respiratory epithe-
lium, as shown by comparison of means in Figure 1.
3.3 Relative abundance of PTC transcripts
estimated using PTC specific primer sets
For the analysis of samples bearing PTC mutations in heterozygos-
ity with non-F508del CFTR mutations (i.e., PTC/other or PTC/PTC
as opposed to PTC/F508del), we designed primers to discriminate
between the six most commonly encountered PTC mutations (E60X,
G542X, R553X, R1162X, Y1092X, and W1282X) and the opposing
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E60X c.178G>T 1 (3) 39% 36.1%
365insT c.233_234insT 1 (3) 27% 63%
G542X c.1624G>T 2 (3, 3) 20.4% 74.4%
2183AA>G c.2051_2052delAAinsG 1 (4) 20% 75%
E730X c.2188G>T 1 (1) 26.4% 64.1%
W846X c.2537G>A 1 (1) 37% 41.3%
Y1092X c.3276C>A 1 (3) 17.4% 78.9%
R1162X c.3484C>T 4 (3,3,3,3) 27.3% (±3.6) 62.4%
W1282X c.3846G>A 2 (3,3) 26% 64.9%
Intronic / Splicing
711+1G>T c.579+1G>T 2 (3,2) 52.5% N/A
2789+5G>A c.2657+5G>A 3 (3,3,1) 21.7% (±1.2) 72.3%
3849+10kbC>T c.3717+12191C>T 1 (1) 23% 70.1%
3500-2A>G c.3368-2A>G 1 (3) 23% 70.1%
Other (non PTC)
dele2,3_21 kb c.54-5940_273+10250del21kb 1 (3) 54% N/A
A455E c.1364C>A 1 (3) 49% N/A
R334W c.1000C>T 2 (2, 2) 55% N/A
aBased onNCBI Reference Sequence for CFTR: NM_000492.3.
F IGURE 1 Mean relative abundance of non F508del CFTR
transcripts with or without PTCmutations, in respiratory cells (fresh
and cultured) versus organoids. Means of relative CFTRmRNA
abundance for non-F508del transcript as measured by qRT-PCR using
F508del primer set are shown: data is summarized from Tables 1 and
2. Each triangle represents themean value for onemutation and one
cell type (as shown in key). Groupmeans were 33.06% (n= 10) and
55.95% (n= 6) for PTC and non-PTC bearing respiratory cells, and
25.68% (n= 12) and 52.63% (n= 4) for PTC and non-PTC bearing
intestinal organoids, respectively
allele (see Methods and Supporting Information Table S1). These
primers had lower degrees of allele specificity than the F508del spe-
cific primers: the proportion of nonspecific amplification of wt-CFTR
plasmid DNA bymutation specific primers compared to the respective
wt primers after 40 cycles of qRT-PCR was 1:11666 for the F508del
primer set, but lower for E60X (1:6841), G542X (1:189), W1282X
(1:128), R1162X (1:117), Y1092X (1:85), and R553X (1:17) primers.
Data obtained from the PTC mutation specific primers (Support-
ing Information Table S3) generally supported the data obtained
using the F508del primer set, but with some differences. In some
cases (F508del/PTC genotypes), it was possible to apply both primer
sets to the same samples. Some such data were very similar (e.g.,
G542X/F508del HNE data and W1282X/F508del organoid data),
thereby validating the PTC-specific primers. Comparison of a set of
HNE samples bearing the G542X/F508del genotype for which data
were obtained for both F508del and G542X specific primers showed
no significant difference (n = 6, mean% ± SEM) for F508del primers =
30.2± 3.9%, mean for G542X primers= 25.5± 3.5%: see Figure 2a).
In other cases, however, the PTC specific primer sets underesti-
mated (e.g., R1162X/F508del and Y1092X/F508del organoid data) or
overestimated (e.g., E60X/F508del organoid data) the quantification
data provided by the F508del primers (see Figure 2b).
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F IGURE 2 Relative abundance of PTC bearing CFTR transcripts estimated using F508del and PTC primer sets. (a) Allele-specific CFTRmRNA
abundance wasmeasured for the same set of HNE samples with the F508del/G542X genotype (n= 6). Mean± SEM are shown (30.2± 3.9% for
F508del primers, 25.5± 3% for G542X primers: not significantly different). (B) Other PTC primer sets vary in their relative efficiencies.
F508del/PTC samples were amplified for samples with E60X, G542X, Y1092X, R1162X, andW1282XCFTR, using F508del primers and the
respective PTC primer sets. Abundance of mRNAs derived from PTC alleles are similar to that of F508del/G542X samples, but E60X primers
overestimate, while R1162X and Y1092X primers underestimate values given by F508del primers due to different relative efficiencies. Data here
are compiled from Tables 1 and 2 and Supporting Information Table S3, and do not necessarily represent the same samples for alternative primer
sets
F IGURE 3 Effect of position of PTCmutations along CFTR gene on relative abundance of PTC-transcripts. Percentage degradation of mRNA
derived from PTC bearing alleles plotted against position of PTC causingmutations (nonsense: X, frameshift: F, or Splicing: S) in CFTR gene. Only
data points from Tables 1 and 2, obtained using F508del primers either in respiratory cells (dark triangles) or organoids (clear triangles) are shown.
The order of mutations shown is as follows: S4X (X, ex. 1), dele2,3_21 kb (F, ex. 2), E60X (X, ex. 3), 365insT (F, ex. 3), G542X (X, ex. 12), R553X (X, ex.
12), 1811+1.6kbG>A (S, intr. 12), 2183AA>G (F, ex. 14), E730X (X, ex. 14),W846X (X, ex. 15), 2789+5G>A (S, intr. 16), Q890X (X, ex. 17),
3272-26A>G (S, intr. 19), Y1092X (X, ex. 20), 3500–2A>G (S, intr. 20), R1162X (X, ex. 22), 3849+10kbC>T (S, intr. 22), 3886insA (F, ex. 23),
W1282X (X, ex. 23)
3.4 Influence of PTC position onmRNA abundance
Measured levels of mRNA abundance were not influenced by whether
the PTC resulted from a nonsense, frameshift, or splicing mutation.
Next, we assessed whether either the location of each PTC causing
mutation along the CFTR gene (Figure 3) might be a factor influencing
NMD. A distance of less than 50–55 nt to the last exon–exon junction
has been reported to enable NMD avoidance (Nagy & Maquat, 1998).
However, among the tissues available for testing, none had mutations
occurring in the penultimate exon. The only mutations giving any
indication that they might escape NMD to some degree were S4X,
dele2,3_21 kb, and possibly E60X, each of which could be associ-
ated with the use of an alternative initiation codon, such as met150
(Ramalho et al., 2009).
3.5 Whole CFTRmRNA abundance versus
CFTR genotype
In order to determine whether the observed reduction in abun-
dance of CFTR PTC-RNAs caused an overall reduction in CFTR
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F IGURE 4 Whole CFTR abundancemeasured in HNE cells grouped
bymutation type. Relative expression of whole CFTRmRNAwas
measured in native HNE cells from healthy controls, CF patients with
one PTC causing CFTR allele and CF patients with no PTC causing
allele (mean± SEM). There was a significant (P< 0.05) reduction of
CFTRmRNA for the CF-PTC group compared to the CF-non-PTC
group (dotted line)
mRNA abundance, relative expression of total CFTR mRNA was
measured in native HNE cells from healthy controls (Non-CF Ctrl;
n = 5), CF patients with one PTC causing allele (CF-PTC; n = 7:
genotypes G542X/F508del; 2183AA>G/F508del; 3886insA/F508del;
Y1092X/P205S; 2x W1282X/H1079P; 3849+10kbC>T/F508del),
and CF patients with no PTC causing allele (CF-non PTC; n = 6:
genotypes A561E/F508del; 2x R334W/F508del; P205S/F508del;
R560S[c.1680A>C]/R560S; F508del/F508del). As shown in Figure 4,
therewas indeed a significant reduction (approximately 38%, P< 0.05)
of total CFTR mRNA for the CF-PTC group compared to the CF-non
PTC group, representing 76% degradation of mRNA derived from
the PTC allele, in agreement with our observations for individual
mutations.
4 DISCUSSION
Using an allele specific qRT-PCR approach, the present study demon-
strates that abundance of mRNA derived from CFTR alleles bearing
PTC causingmutations is reduced compared to that derived from non-
PTCalleles, and generally PTC-mRNA levels are just around21–38%of
the total CFTRmRNA in native HNE cells, with similar levels (17–39%)
seen in intestinal organoids. The observed range of reduction is similar
for transcripts with PTCs introduced by nonsense, frameshift, or splic-
ingmutations, and is independent ofmutation position, bothwithin the
CFTR gene and, for most nonsense mutations, within the exon, regard-
ing the distance to the next downstream exon–exon junction. There
is, however, considerable variation in PTC mRNA abundance among
individuals with the same PTCmutation, for example, a range of 13.5–
38.2% for HNE samples with the G542X/F508del genotype from 10
different individuals.
These results are consistent with previous estimates that NMD
reduces the abundance of PTC containing mRNAs to from 5% to 25%
of non-PTC transcripts (Kuzmiak & Maquat, 2006). It is also known
that NMD varies among patients bearing distinct CFTR mutations
(Linde, Boelz, Nissim-Rafinia, et al., 2007a), and that the efficiency
of NMD may also vary between cell types (Linde, Boelz, Neu-Yilik,
et al., 2007b). More recently it has been shown that NMD factors
may be suppressed during differentiation, which may be of relevance
to NMD in airway epithelium (Lou et al., 2016), and it is becoming
clear that NMD is not just an RNA surveillance machinery eliminat-
ingPTCs, but also a posttranscriptional geneexpression regulation sys-
tem that selectively degrades mRNAs implicated in various specific
cell functions (Han et al., 2018). Our data suggest that in the case of
PTC mutations in CFTR, there is a balance between NMD and gene
transcription, which favors reduced accumulation, but not outright
elimination of the PTC bearing mRNA transcripts. A restricted tran-
scriptional shutdown experiment confirmed that CFTRmRNA bearing
the G542X PTC has a lower half-life compared to F508del in intesti-
nal organoids (Supporting Information Figure S1), as expected. The
extent to which this reduced stability varies between PTCs, and how
such variations might specifically hamper read-through efficacy has
yet to be tested, but the outcome is that for most PTC causing muta-
tions a considerable amount of transcript is still available. These tran-
scriptsmight thus be translated into truncated protein, of some poten-
tial toxicity to the cell. However, in turn they may also serve for PTC
read-through based therapeutic approaches, a fact which is of rele-
vance to the future application of CFTR Class I mutation correction
strategies.
The broad agreement between values obtained inHNEs and intesti-
nal organoids contributes to validating the use of the latter model
as a surrogate for the respiratory epithelium in studies of CFTR
gene expression and NMD, and by extension for testing therapeutic
approaches as already demonstrated for Class I mutations (Zomer-
van Ommen et al., 2016) and other mutation classes (Dekkers et al.,
2016). Nevertheless, it can be noticed that slightly higher levels
of PTC degradation were measured in organoids than in HNE (see
Figures 1 and 3), and it would be interesting to know if this correlates
with the specific relative expression ofNMD factors in these cell types.
Somemutationsproducedapparentlydiscrepantdata: S4Xandpos-
sibly E60Xappear to escapeNMD-related degradation,which could be
the result of alternative initiation codon usage as previously suggested
for othermutations occurring in the region around the initiation codon
(Ramalho et al., 2009). However, for S4X, it is more likely to be by
virtue of its position in the fourth codon of CFTR, in close proximity to
the start codon, which itself is a major determinant of NMD avoidance
(Inácio et al., 2004). On the other hand, the large deletion mutant
dele2,3_21 kb, predicted to cause a frameshift and a PTC early in exon
4 was also found here to evade enhanced degradation. Interestingly,
this was also observed in an original study of this mutation in HNE
samples (Dörk et al., 2000), which suggested re-initiation of translation
at an internal AUG codon at nt position 150 in exon 4, similarly to the
above situation, as a possible explanation for the lack of degradation of
this transcript. Other data served to confirm the relationship between
PTCs and NMD: the 1812-1G>A and 711+1G>T splicing mutations
are associated with skipping of exons 13 and 5, respectively (Felício,
Ramalho, Igreja, &Amaral, 2017; Fonknechten, Chomel, Kitzis, Kahn, &
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Kaplan, 1992). As these two exons possess ‘whole numbers’ of codons
(i.e., nucleotide numbers that are multiples of 3), neither the introduc-
tion of PTCs nor the consequent triggering of NMD are expected.
The values obtained for relative abundance of non-PTC muta-
tions (including P205S, R334W, and A561E) in heterozygosity with
F508del in both HNEs and organoids are generally higher than 50%
of total CFTR mRNA (see Figure 1), suggesting that F508del-CFTR
mRNA is itself subject to a reduction in abundance. The average ratio
of F508del/non-PTC transcripts is 79% (HNE) and 90% (organoids),
similar to a figure of 87% measured in HNE that we have previously
reported (Ramalho et al., 2002). It should therefore be borne in mind
that abundance of mRNA from PTC alleles as presented here is possi-
bly overestimatedwhenmeasured against the F508del allele. Thismay
help explainwhy some values obtained usingmutation specific primers
seem low compared to values for the same mutations using F508del
primers (see Supporting Information Table S3). Further optimization of
the PTC mutation specific primers is desirable: each primer set has a
specific level of substrate efficiency, shown by different ratios of wt-
CFTR plasmid amplification by WT versus mutant primers. Improve-
ments in specificity might be achieved by introduction of additional
or alternative mismatches into the central primer regions. However,
sequencing based methods such as RNAseq might also provide an
alternative quantitative approach applicable for any combination of
CFTR genotypes.
We have shown that mRNAs transcribed from PTC bearing CFTR
alleles occur with a consistently reduced abundance compared to non-
PTC alleles, presumably being subject to NMD. This is equally the case
in native HNE cells and cultured intestinal organoids derived from
rectal biopsies. Since the precise values of relative PTC-mRNA abun-
dance were subject to twofold variations between individuals with the
same CFTR genotype, we propose that individual NMD levels would
be useful in predicting the efficacy of mutation-specific CFTR modu-
lator therapies, namely those using read-through approaches. Further-
more, intestinal organoids and HNE cells would be equally suitable for
such measurements. Recent work confirmed that G418 read-through
induced limitedCFTR function for E60X/4015delATTTorganoids lack-
ing residual CFTR function (Zomer-van Ommen et al., 2016). This
was enhanced by CFTRmodulators VX-770/809 confirming that even
unstable PTC mRNA can be sufficient for successful read-through by
pharmacological agents, especially if further boostedby correctors and
potentiators. However, future work on PTC mutation specific tran-
script stability is important to identify the variantsmost likely to bene-
fit from these approaches.
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